ArticleTanaffos2025
Interleukin-1 and Interleukin-8 are Prominent Inflammatory Markers in Patients with Cystic Fibrosis and Non-Cystic Fibrosis.
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchiectasis is characterized by pathological inflammation and infection that cause thickening and dilation of the airways. It is categorized into cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). Given the disease's inflammatory nature, this study aimed to assess the levels of interleukin-1 (IL-1), IL-8, and tumor necrosis factor-alpha (TNF-α) in CF and NCFB patients compared to a healthy control (HC) group. Materials and Methods: A total of 35 bronchiectasis patients (18 with CF and 16 with NCFB) and 18 individuals in the HC group were selected based on specific inclusion and exclusion criteria. After receiving informed consent, the levels of IL-1, IL-8, and TNF-α in serum and broncho-alveolar lavage (BAL) fluid were measured using ELISA. Additionally, spirometry results for the study participants were recorded before and after bronchoscopy. Results: Significant differences were observed in serum IL-8 (p = 0.018) and in BAL IL-1 and IL-8 levels (p = 0.018 and p < 0.0001, respectively). A notable positive correlation was found between serum IL-1 and both serum and BAL IL-8 (p < 0.0001). Similarly, serum IL-8 showed a significant positive correlation with its BAL levels (p = 0.007). Conclusion: Findings from this study suggest that elevated IL-1 in the lungs is a key factor in bronchiectasis-related inflammation, and the increase in IL-8 may occur via an IL-1-dependent pathway. The heightened levels of IL-8 in BAL and serum among bronchiectasis patients align with known neutrophilia in these cases. Spirometry results showed no significant association with these cytokine increases, indicating that relying solely on spirometry may be insufficient for monitoring inflammation in bronchiectasis patients.
Indexed as
Identifiers
42027434PMC13102295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.